Comparative Pharmacology
Head-to-head clinical analysis: DENTIPATCH versus ZYNRELEF KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENTIPATCH versus ZYNRELEF KIT.
DENTIPATCH vs ZYNRELEF KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic agent that inhibits sodium ion influx into nerve cells, blocking nerve conduction and pain sensation.
Zynrelef is a fixed-dose combination of bupivacaine and meloxicam. Bupivacaine blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction. Meloxicam inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and inflammation.
Apply one 10 mg/10 cm² transdermal patch to intact skin once daily, typically in the morning; remove after 24 hours and replace with a new patch.
Instillation into the surgical site: 20 mL (300 mg bupivacaine and 9.3 mg meloxicam) as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 hours; clinically, steady-state is achieved after 2–3 days of daily application.
Terminal half-life of bupivacaine (component) is 3.5 hours; for meloxicam (component) is 20 hours. Clinical context: bupivacaine half-life prolonged in hepatic impairment; meloxicam half-life prolonged in elderly (up to 25 hours)
Approximately 60% of the dose is excreted renally as unchanged drug and metabolites; the remainder is eliminated via biliary/fecal routes.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Local Anesthetic
Local Anesthetic and NSAID Combination